SAMBAZON® Brings the Alegria to Life with Vibrant Experiential Pop-Up in San Diego -- Thousands of Fans, Influencers, and Athletes Join the Celebration; Açaí Bowls, Smoothies, and Exclusive Merch Take Center Stage at Malibu Farm, Seaport Village
SAN DIEGO, May 30, 2025 /PRNewswire/ -- SAMBAZON®, the pioneer of Açaí, made waves in Southern California this past weekend with its first-ever Experiential Pop-Up Activation, a high-energy, three-day celebration held May 16th – 18th at the iconic Malibu Farm at Seaport Village.
Dubbed Taste the Alegria, the event was an immersive celebration of all things SAMBAZON® — with complimentary Açaí bowls and smoothies, custom merch giveaways, live music from DJ Romar, and vibrant photo moments that captured the brand's signature purple-powered joy.
The event drew thousands of fans, families, and lifestyle influencers — along with a slate of high-profile guests including Sophia Culpo, Tia Blanco, Dylan Barbour, Coco Ho, Kourtney Turner, Turnip Vegan, and Chad & Natalie Kerley — who shared their experiences across social media, helping the event reach millions of followers nationwide.
"Best time at the @sambazon event!! When you eat SAMBAZON, you're not only nourishing your body — you're standing for sustainability," shared pro surfer Tia Blanco.
"Go check it out — they're serving up free smoothie bowls, exclusive merch, and all the good vibes," said model and wellness creator Sophia Culpo in her weekend post.
Saturday Morning included a partnership with Pacific Beach Run Club which brought hundreds of runners to Seaport Village to participate in an early morning Purple inspired 5k.
"The pop-up looked AMAZING and the execution was flawless. I know our crew will be talking about the event for years to come." Said PBRC Founder and CEO Todd Barnett.
All attendees were treated to exclusive offerings, including custom-embroidered SAMBAZON® denim jackets for the first 100 guests each day, delicious Açaí Bowls and Smoothies for all, tons of merch, and a sneak peek at the brand's newest product launch: All-In-One, Ready-to-Serve Açai & Smoothie bowls designed for convenient, on-the-go superfood nourishment.
SAMBAZON® Co-Founder and CEO Ryan Black made an appearance to connect with fans and underscore the brand's mission-driven roots. "We're not just building a brand — we're building a movement," said Ryan Black, SAMBAZON® Co-Founder and CEO, who attended the event. "This pop-up was our way of showing up in real life to celebrate our community and share the joy of our product — sustainably sourced, ethically made, and powered by purple."
The Taste the Alegria experience marks the first of many public-facing activations for SAMBAZON® as the brand continues to expand its presence in the wellness and lifestyle space.
Interested in grabbing a delicious SAMBAZON® Açaí Bowl in San Diego? Flagship Location in Cardiff, our kiosk at Petco Park Section 113, and our newest bowl shop opening this summer at San Diego International Airport."
View original content to download multimedia:https://www.prnewswire.com/news-releases/sambazon-brings-the-alegria-to-life-with-vibrant-experiential-pop-up-in-san-diego--thousands-of-fans-influencers-and-athletes-join-the-celebration-acai-bowls-smoothies-and-exclusive-merch-take-center-stage-at-malibu-farm-s-302469762.html
SOURCE SAMBAZON
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
USI Partners with Customer on GPS Bike Computer Project, Delivering Durable Rugged Design
SHANGHAI, June 4, 2025 /PRNewswire/ -- Universal Scientific Industrial (Shanghai) Co., Ltd., USI, a global leader in electronic design and manufacturing services, is collaborating with a customer to develop a GPS bike computer through its Joint Design Manufacturing (JDM) service. The project responds to increasing global demand for high-performance, durable cycling electronics in a rapidly expanding market. According to a report by Global Industry Analysts, Inc., the global market for GPS bike computers was valued at $1.2 billion in 2024 and is expected to grow to $1.7 billion by 2030, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030. This market is driven by rising interest in outdoor activities, fitness tracking, and smart mobility solutions. However, durability remains a top concern among end-users, particularly cyclists who operate in extreme environmental conditions and expect reliable performance from their gear. With over two decades of experience in designing and manufacturing rugged, thinner, and lighter devices, USI is uniquely positioned to address these challenges. The company works closely with customers to understand their pain points and long-term product strategies. By analyzing the product roadmap and selecting key components, USI's engineering team proposes a rugged design that emphasizes durability, reliability, and resistance to harsh conditions. "Our JDM model allows customers to benefit from USI's turnkey solutions—from concept design and system integration to volume production," said Mark Zou, the Director of the Vertical Mobility Solutions Center, USI. For the GPS bike computer project, we delivered a robust design solution that meets both functional performance and ruggedness requirements, ensuring the device can withstand tough terrains, vibration, and weather elements." USI's continued investment design expertise and customer-centric innovation supports the growing needs of the smart mobility market and reflects its commitment to quality, reliability, and partnership. About USI (SSE: 601231) USI, Universal Scientific Industrial (Shanghai) Co., Ltd., is a global leader in electronic design and manufacturing as well as a leader in the field of SiP (System-in-Package) technology. With Asteelflash and Hirschmann Car Communication, USI has 30 production and service locations across four continents of Asia, Europe, the Americas, and Africa, and offers customer diversified electronic products with D(MS)2 services: Design, Manufacturing, Miniaturization, Industrial software, and hardware Solutions, and material procurement, logistics and maintenance Services. USI is a subsidiary of ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX). To learn more, please visit and engage with us on LinkedIn and YouTube. View original content: SOURCE USI Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Airbnb generates an estimated $590 million in Kentucky in 2024
KENTUCKY (FOX 56) — Airbnb saw a record year in 2024. The platform has paved the way for tourists to visit off-the-beaten-path destinations since its launch in 2007. Read more of the latest Kentucky news Data shows that the surge in popularity is predominantly in less saturated areas or for travelers in need of more flexible accommodations, and its demand continues to rise year after year, according to AirDNA, the leading provider of data and analytics for the short-term rental industry. In 2024, it welcomed its two billionth guest nationwide. 'In doing so, they're also supporting local economies—from small towns to big cities—and driving meaningful economic impact into every corner of the country,' Airbnb wrote. 'According to newly released estimates, travel on Airbnb generated more than $90 billion in economic activity across the United States in 2024—a record figure reflecting the total contribution driven by guests, hosts, and the businesses guests support.' A new study breaks down Airbnb's economic impact in 2024 amid battles against short-term rental restrictions. In November 2024, FOX 56 reported that Lexington supports over 1,000 short-term rentals, of which, at the time, only 729 were licensed. Airbnb generates an estimated $590 million in Kentucky in 2024 Nelson County paramedic dies after on-duty crash Vikings' Purple People Eater, Kentucky native, Jim Marshall, dies at 87 According to Airbnb, in Kentucky, it contributed: $590.5 million in total contribution to gross domestic product 8,700 jobs supported $146.5 million in tax revenue The typical guest in the U.S. spent more than $775 per trip on other goods and services like restaurants, entertainment, shopping, and other local businesses. That influx of visitor spending helped support more than one million estimated jobs nationwide last year, helping to generate over $52 billion in labor income,' the study reads. Airbnb said that short-term rental regulations have caused major cities like New York to forego as much as $82 million. Click here for a state-by-state view of Airbnb's economic impact. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Baseline characteristics 50 mg denifanstat, oral, oncedaily (n=240) Placebo, oral, once daily (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Efficacy endpoints (1) 50 mg denifanstat, oral, once daily (n=240) Placebo, oral,once daily (n=240) Placebo adjusted p value Percent treatment success (2) (primary endpoint) 33.2 14.6 18.6 <0.0001 Percent reduction from baseline in total lesion count (primary endpoint) 57.4 35.4 22.0 <0.0001 Percent reduction from baseline ininflammatory lesion count (primary endpoint) 63.5 43.2 20.3 <0.0001 Percent reduction from baseline in non-inflammatory lesion count (key secondary endpoint) 51.9 28.9 23.0 <0.0001 Absolute reduction from baseline intotal lesion count (secondary endpoint) 58.3 36.2 22.1 <0.0001 Absolute reduction from baseline in inflammatory lesion count (secondaryendpoint) 26.6 18.4 8.2 <0.0001 Notes: (1) All efficacy endpoints are least square means.(2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Category Denifanstat (n=240) Sarecycline(1) (n=1002) Doxycycline(2) (n=216) Clascoterone cream(3) (n=722) Baseline characteristics Total lesion count 102.2 72.4 71.7 103.6 Inflammatory lesion count 42.1 30.0 33.6 42.7 IGA=3 (moderate), % 85.8 85.2 93.5 82.7 IGA=4 (severe), % 14.2 14.9 6.5 17.3 Efficacy endpoints at week 12 Placebo-adjusted percenttreatment success 18.6 9.4 6.7 11.6 Placebo-adjusted percent reductionfrom baseline in total lesion count 22.0 NA 7.6 11.9 Placebo-adjusted percent reductionfrom baseline in inflammatorylesion count 20.3 15.6 7.3 12.8 Placebo-adjusted percent reduction from baseline in non-inflammatorylesion count 23.0 4.5 NA 11.4 Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA ( The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.(3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
